[go: up one dir, main page]

MX2009004858A - Forma de dosificacion de imatinib procesada en fusion. - Google Patents

Forma de dosificacion de imatinib procesada en fusion.

Info

Publication number
MX2009004858A
MX2009004858A MX2009004858A MX2009004858A MX2009004858A MX 2009004858 A MX2009004858 A MX 2009004858A MX 2009004858 A MX2009004858 A MX 2009004858A MX 2009004858 A MX2009004858 A MX 2009004858A MX 2009004858 A MX2009004858 A MX 2009004858A
Authority
MX
Mexico
Prior art keywords
imatinib
melt
dosage form
dosage forms
processed
Prior art date
Application number
MX2009004858A
Other languages
English (en)
Inventor
Harald Hach
Joerg Breitenbach
Joerg Ogorka
Norbert Steiger
Ulrich Westedt
Martin Knobloch
Ralf Altenburger
Nicoletta Loggia
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of MX2009004858A publication Critical patent/MX2009004858A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención proporciona una forma de dosificación que comprende una mezcla procesada en fusión de (a) una cantidad farmacéuticamente efectiva de imatinib o una sal del mismo, (b) por lo menos un aglomerante polimérico, y (c) por lo menos un surfactante no iónico farmacéuticamente aceptable. La invención ofrece formas de dosificación de imatinib con alta carga de fármaco que pueden prepararse de manera sencilla y eficiente, formas de dosificación de imatinib a partir de las cuales el principio activo es liberado en forma esencialmente independiente del pH, y formas de dosificación de imatinib de liberación prolongada.
MX2009004858A 2006-11-09 2007-11-08 Forma de dosificacion de imatinib procesada en fusion. MX2009004858A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06023367A EP1920767A1 (en) 2006-11-09 2006-11-09 Melt-processed imatinib dosage form
PCT/EP2007/062100 WO2008055965A1 (en) 2006-11-09 2007-11-08 Melt-processed imatinib dosage form

Publications (1)

Publication Number Publication Date
MX2009004858A true MX2009004858A (es) 2009-05-21

Family

ID=38291110

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004858A MX2009004858A (es) 2006-11-09 2007-11-08 Forma de dosificacion de imatinib procesada en fusion.

Country Status (13)

Country Link
US (1) US8841303B2 (es)
EP (2) EP1920767A1 (es)
JP (1) JP5280369B2 (es)
CN (3) CN101594851B (es)
AU (1) AU2007316557B2 (es)
BR (2) BRPI0718521A2 (es)
CA (1) CA2668775C (es)
ES (1) ES2565036T3 (es)
MX (1) MX2009004858A (es)
PL (1) PL2086516T3 (es)
RU (1) RU2468788C2 (es)
WO (1) WO2008055965A1 (es)
ZA (1) ZA200903929B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1920767A1 (en) 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
GB2488788B (en) * 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
CN102836159B (zh) * 2011-06-24 2014-12-10 南京圣和药业股份有限公司 达沙替尼分散体及其制备方法和其在片剂中的应用
US9216172B2 (en) 2011-08-04 2015-12-22 National Cancer Center Method for determining effectiveness of cancer treatment by assessing the presence of a KIF5B-RET chimeric gene
CA2856692C (en) 2011-11-24 2016-06-28 Imuneks Farma Ilac Sanayi Ve Ticaret A.S. Imatinib solid dosage forms reconstituted just before use
ES2946549T3 (es) 2012-01-13 2023-07-20 Xspray Pharma Ab Publ Composición farmacéutica de nilotinib
CN103301067B (zh) * 2012-03-15 2018-09-11 苏州泽璟生物制药有限公司 一种改善吸收性能的固体分散体及其制备
JP5928159B2 (ja) * 2012-05-28 2016-06-01 ニプロ株式会社 医薬組成物
KR101386697B1 (ko) 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
CN106074554A (zh) * 2015-04-27 2016-11-09 陈骏英 一种用于治疗食管癌的药物及使用方法
CN104888228A (zh) * 2015-05-29 2015-09-09 连云港杰瑞药业有限公司 一种甲苯磺酸索拉非尼固体分散体及其制备方法
CN105126111A (zh) * 2015-09-30 2015-12-09 清华大学 提高索拉非尼生物利用度的制剂
CN106974890A (zh) * 2016-01-15 2017-07-25 常州方楠医药技术有限公司 一种无定型舒尼替尼l-苹果酸盐与药用辅料的固体分散体及其制备方法
ES2935158T3 (es) * 2016-03-17 2023-03-02 Sun Pharmaceutical Ind Ltd Composición farmacéutica de nilotinib
CN107157941B (zh) * 2017-05-16 2020-12-25 北京化工大学 一种达沙替尼纳米制剂及其制备方法
CN110801434A (zh) * 2019-10-31 2020-02-18 金华职业技术学院 一种冻干法制备甲苯磺酸拉帕替尼固体分散体的方法
CA3168667A1 (en) 2020-01-24 2021-07-29 Nanocopoeia, Llc Amorphous solid dispersions of dasatinib and uses thereof
EP4096791A1 (en) 2020-01-31 2022-12-07 Nanocopoeia LLC Amorphous nilotinib microparticles and uses thereof
CN112294971B (zh) * 2020-02-20 2022-02-01 深圳市泰力生物医药有限公司 具有改进的溶解性的尼洛替尼组合物
CN111358952B (zh) * 2020-04-15 2022-03-15 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种抗肿瘤药物组合物及其制剂和应用
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CA3155855A1 (en) * 2020-12-07 2022-06-07 Tianjin Creatron Biotechnology Co., Ltd. Sorafenib pharmaceutical composition with high bioavailability and use thereof
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4384661A (en) * 1982-04-07 1983-05-24 Page Edward H Aerosol water-based paint compositions
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
DE19812688A1 (de) * 1998-03-23 1999-09-30 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
DE69917618T2 (de) * 1998-04-03 2005-06-23 Egalet A/S Zusammensetzung mit kontrollierter wirkstoff-freisetzung
DE19929361A1 (de) * 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
GEP20053427B (en) * 1999-12-23 2005-01-25 Pfizer Prod Inc Pharmaceutical Compositions Providing Enhanced Drug Concentrations
FR2827770B1 (fr) * 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
RU2231015C1 (ru) * 2002-10-03 2004-06-20 Федеральное Государственное унитарное предприятие "Государственное научно-производственное предприятие "Сплав" Устройство угловой стабилизации реактивного снаряда
WO2004069138A2 (en) * 2003-02-03 2004-08-19 Novartis Ag Pharmaceutical formulation
BRPI0410745A (pt) * 2003-05-22 2006-06-27 Abbott Lab inibidores de indazol, benzisoxazol e benzisotiazol quinase
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
FR2861992B1 (fr) * 2003-11-10 2007-07-20 Sanofi Synthelabo Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
WO2006040779A2 (en) * 2004-10-11 2006-04-20 Natco Pharma Limited Controlled release gastric floating matrix formulation containing imatinib
WO2006054314A1 (en) * 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
AU2006255177A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate imatinib mesylate formulations
EP1920767A1 (en) 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form

Also Published As

Publication number Publication date
AU2007316557A1 (en) 2008-05-15
CN101594852B (zh) 2013-04-03
CN101594851A (zh) 2009-12-02
JP2010509288A (ja) 2010-03-25
EP2086516B1 (en) 2016-01-06
US20100240672A1 (en) 2010-09-23
CN101594852A (zh) 2009-12-02
BRPI0718521A2 (pt) 2013-11-19
BRPI0718523B1 (pt) 2022-03-03
ES2565036T3 (es) 2016-03-30
WO2008055965A1 (en) 2008-05-15
CN101594851B (zh) 2013-01-02
US8841303B2 (en) 2014-09-23
EP2086516A1 (en) 2009-08-12
CA2668775A1 (en) 2008-05-15
RU2468788C2 (ru) 2012-12-10
RU2009121653A (ru) 2010-12-20
AU2007316557B2 (en) 2013-10-31
PL2086516T3 (pl) 2016-08-31
JP5280369B2 (ja) 2013-09-04
BRPI0718523B8 (pt) 2022-09-13
ZA200903929B (en) 2010-03-31
BRPI0718523A2 (pt) 2013-11-19
EP1920767A1 (en) 2008-05-14
CN102512680A (zh) 2012-06-27
CA2668775C (en) 2014-08-12

Similar Documents

Publication Publication Date Title
MX2009004858A (es) Forma de dosificacion de imatinib procesada en fusion.
WO2006124047A3 (en) Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
IL183357A0 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
MX2010008138A (es) Forma de dosis farmaceutica.
UA91376C2 (ru) Рецептура с контролируемым высвобождением
AU2003274681A8 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
IL187475A (en) A form of oral administration containing one population of micro-particles to release a variable of at least one active anesthetic and a second population of micro-particles containing at least one depressant and their use
PT2040755E (pt) Combinação de um inibidor de colinesterase e um composto com afinidade para o receptor 5-ht6
WO2006084164A8 (en) Gastric retention and controlled release delivery system
IL183658A0 (en) Solid dosage form comprising proton pump inhibitor and suspension made thereof
WO2009063222A3 (en) Solid compositions
WO2008045238A3 (en) Stabilized therapeutic small helical antiviral peptides
WO2007150075A3 (en) Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
IL188744A0 (en) High drug load formulations and dosage forms
IL217713A0 (en) Compounds and compositions for delivering active agents
ZA200900929B (en) Microparticles based on an amphiphilic copolymer and on active ingredient(s) with modified release and pharmaceutical formulations containing same
IL191758A0 (en) Composition with sustained release of the active ingredient, process for the preparation thereof and use thereof
IL184448A0 (en) Pharmaceutically active phosphate binders, their manufacture, compositions containing them and their use
UA89315C2 (en) Butylbenzene phthalein intravenous emulsion
WO2008003050A3 (en) Gallium nitrate formulations
MX2007002898A (es) Tableta con liberacion gastrointestinal controlada en sitio y tiempo del ingrediente activo.
WO2008056375A3 (en) Pharmaceutical formulations comprising valsartan
EP1731609A4 (en) INHIBITOR OF THE EXPRESSION OF RAD51, MEDICAMENT CONTAINING THE INHIBITOR AS ACTIVE INGREDIENT AND USE THEREOF
PL1795186T3 (pl) Preparat leku zawierający flupirtynę o kontrolowanym uwalnianiu substancji czynnej
WO2007121471A3 (en) Dialkyl ether delivery agents

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights
PD Change of proprietorship

Owner name: NOVARTIS AG.*